US-China Pharmaceutical Venture Ascletis Receives Record-Level Research and Development Grant from Hangzhou

US-China Pharmaceutical Venture Ascletis Receives Record-Level Research and Development Grant from Hangzhou


RESEARCH TRIANGLE PARK, N.C. & HANGZHOU, China, Jan 04, 2012 (BUSINESS WIRE) -- Ascletis, Inc., a U.S.-China joint venture pharmaceutical company, today announced it has received a record level research and development grant from Hangzhou National Hi-Tech Industrial Development Zone (HHTZ) under that organization's "5050 Plan." The 10 million RMB grant (approximately US$1.6 million) is the largest startup company grant in the history of the 5050 Plan, whose goal is to incentivize and assist start-up, technology-based companies within HHTZ, Hangzhou, Zhejiang Province.

"This grant recognizes the outstanding opportunity offered by Ascletis to create a world-class pharmaceutical company in Hangzhou that will develop innovative products both for China and for the rest of the world," said Sheng Kong-Liang, Director of Organization of HHTZ. "Ascletis has made rapid progress in R&D since its formation in early 2011. Not only have they raised a $100 million Series A financing from private investors, but they have assembled a world class team of globally experienced pharmaceutical developers."

"We are grateful for this recognition and support from HHTZ," said Jinzi J. Wu, Ph.D., Ascletis' President and Chief Executive Officer. "With such local governmental partners providing strong support to Ascletis' business, as well as our collaborators in Research Triangle Park, North Carolina, we are well positioned to address the large market potential that exists for innovative drugs, both in China and globally."

About Ascletis, Inc.

Ascletis is a joint venture between U.S. and Chinese entrepreneurs aimed at building a global specialty therapeutics business dedicated to discovering and developing important new treatments for cancer and infectious diseases. Ascletis leverages U.S./European innovation and pharmaceutical/biotech strategic experience and China's capital efficiency with a goal of establishing in the near term a sustainable business and accelerated revenues through the in-licensing, late-stage clinical development, and commercialization of new medicines for the growing Chinese pharmaceutical marketplace. At the same time, the company is building long-term value through the discovery, demonstration of clinical proof-of-concept, and global partnering of novel therapeutics for life-threatening diseases. For more information, please visit http://www.ascletis.com .

 

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.